Liver transplantation for hepatic tumors: A systematic review

World Journal of Gastroenterology

Volumn 20, Issue 18, 2014, Pages 5345-5352

  Ravaioli, Matteo ^a   Ercolani, Giorgio ^a   Neri, Flavia ^a   Cescon, Matteo ^a   Stacchini, Giacomo ^a   Del Gaudio, Massimo ^a   Cucchetti, Alessandro ^a   Pinna, Antonio Daniele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cholangiocarcinoma; Hemangioendothelioma; Hepatoblastoma; Hepatocellular carcinoma; Liver cancer; Liver metastases; Liver transplantation; Neuroendocrine carcinoma

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; FLUOROURACIL;

ADJUVANT THERAPY; BILE DUCT CARCINOMA; BRACHYTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; HEMANGIOENDOTHELIOMA; HEPATOBLASTOMA; HUMAN; LAPAROTOMY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER TUMOR; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIMARY SCLEROSING CHOLANGITIS; RADIATION DOSE; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; ADVERSE EFFECTS; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; GRAFT SURVIVAL; INTRAHEPATIC BILE DUCT; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; GRAFT SURVIVAL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84900406498     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i18.5345     Document Type: Review

References (61)

1. Starzl TE. The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg 2002; 195: 587-610 [PMID: 12437245 DOI: 10.1016/S1072-7515(02)01498-9]
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]
3. United Network for Organ Sharing. Available from: URL: http://www.unos.org
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
5. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491 [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753]
6. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]
7. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/ S0140-6736(11)61347-0]
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
9. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/ S1470-2045(08)70285-7]
10. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96 [PMID: 12512033 DOI: 10.1053/gast.2003.50016]
11. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10: 36-41 [PMID: 14755775]
12. Ravaioli M, Grazi GL, Ballardini G, Cavrini G, Ercolani G, Cescon M, Zanello M, Cucchetti A, Tuci F, Del Gaudio M, Varotti G, Vetrone G, Trevisani F, Bolondi L, Pinna AD. "Liver transplantation with the Meld system: a prospective study from a single European center. " Am J Transplant 2006; 6: 1572-1577 [PMID:16827857 DOI: 10.1111/j.1600-6143.2006.01354.x]
13. Ravaioli M, Grazi GL, Ercolani G, Cescon M, Del Gaudio M, Zanello M, Ballardini G, Varotti G, Vetrone G, Tuci F, Lauro A, Ramacciato G, Pinna AD. Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. Transplantation 2006; 81: 525-530 [PMID: 16495798 DOI: 10.1097/01.tp.0000198741.39637.44]
14. Roayaie K, Feng S. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl 2007; 13: S36-S43 [PMID: 17969067 DOI: 10.1002/lt.21329]
15. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]
16. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509; discussion 509-511 [PMID: 17717454 DOI: 10.1097/ SLA.0b013e318148c704]
17. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8: 2547-2557 [PMID: 19032223 DOI: 10.1111/ j.1600-6143.2008.02409.x]
18. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-827 [PMID: 18688876 DOI: 10.1002/hep.22412]
19. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22 [PMID: 22047762 DOI: 10.1016/S1470-2045(11)70175-9]
20. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; (3): CD004787 [PMID: 21412886 DOI: 10.1002/14651858.CD004787.pub2]
21. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19: 3872-3882 [PMID: 23840128 DOI: 10.3748/wjg. v19.i24.3872]
22. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]
23. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, Ercolani G, Festi D, Pinna AD. Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012; 256: 706-712; discussion 712-713 [PMID: 23095613 DOI: 10.1097/SLA.0b013e3182724ce8]
24. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, Grazi GL, Pinna AD. "Is portal hypertension a contraindication to hepatic resection?" Ann Surg 2009; 250: 922-928 [PMID: 19855258 DOI: 10.1097/SLA.0b013e3181b977a5]
25. Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F, Ramacciato G, Grazi GL, Pinna AD. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008; 8: 1177-1185 [PMID: 18444925 DOI: 10.1111/j.1600-6143.2008.02229.x]
26. Cucchetti A, Vitale A, Del Gaudio M, Ravaioli M, Ercolani G, Cescon M, Zanello M, Morelli MC, Cillo U, Grazi GL, Pinna AD. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant 2010; 10: 619-627 [PMID: 20121741 DOI: 10.1111/ j.1600-6143.2009.02984.x]
27. Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 2012; 55: 132-140 [PMID: 21932387 DOI: 10.1002/hep.24680]
28. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007; 7: 1601-1608 [PMID: 17511683 DOI: 10.1111/ j.1600-6143.2007.01802.x]
29. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005; 11: 1265-1272 [PMID: 16184545 DOI: 10.1002/lt.20549]
30. Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, Khettry U, Gordon F, Khwaja K, Jenkins R, Pomfret EA. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl 2009; 15: 1861-1866 [PMID: 19938113 DOI: 10.1002/lt.21940]
31. Olthoff KM, Merion RM, Ghobrial RM, Abecassis MM, Fair JH, Fisher RA, Freise CE, Kam I, Pruett TL, Everhart JE, Hulbert-Shearon TE, Gillespie BW, Emond JC. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium. Ann Surg 2005; 242: 314-323, discussion 323-325 [PMID: 16135918]
32. Pichlmayr R, Weimann A, Klempnauer J, Oldhafer KJ, Maschek H, Tusch G, Ringe B. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996; 224: 628-638 [PMID: 8916878 DOI: 10.1097/00000658-1996110 00-00007]
33. Becker NS, Rodriguez JA, Barshes NR, O'Mahony CA, Goss JA, Aloia TA. Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12: 117-122 [PMID: 17963015 DOI: 10.1007/s11605-007-0335-4]
34. Robles R, Figueras J, Turrión VS, Margarit C, Moya A, Varo E, Calleja J, Valdivieso A, Valdecasas JC, López P, Gómez M, de Vicente E, Loinaz C, Santoyo J, Fleitas M, Bernardos A, Lladó L, Ramírez P, Bueno FS, Jaurrieta E, Parrilla P. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg 2004; 239: 265-271 [PMID: 14745336 DOI: 10.1097/01.sla.0000108702.45715.81]
35. Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44: 121-126 [PMID: 10219804 DOI: 10.1016/ S0360-3016(98)00509-4]
36. Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I, Fung JJ, Starzl TE. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998; 187: 358-364 [PMID: 9783781 DOI: 10.1016/S1072-7515(98)00207-5]
37. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6: 309-316 [PMID: 10827231]
38. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2: 774-779 [PMID: 12243499 DOI: 10.1034/j.1600-6143.2002.20812.x]
39. Gu J, Bai J, Shi X, Zhou J, Qiu Y, Wu Y, Jiang C, Sun X, Xu F, Zhang Y, Ding Y. Efficacy and safety of liver transplantation in patients with cholangiocarcinoma: a systematic review and meta-analysis. Int J Cancer 2012; 130: 2155-2163 [PMID: 21387295 DOI: 10.1002/ijc.26019]
40. Schmeding M, Neumann UP. Liver transplantation for intra-and extrahepatic cholangiocarcinoma. Ann Transplant 2013; 18: 1-8 [PMID: 23792495 DOI: 10.12659/AOT.883789]
41. Gores GJ, Darwish Murad S, Heimbach JK, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma. Dig Dis 2013; 31: 126-129 [PMID: 23797134 DOI: 10.1159/000347207]
42. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: is transplantation an option? For whom? J Hepatol 2007; 47: 455-459 [PMID: 17697722 DOI: 10.1016/j.jhep.2007.07.003]
43. Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, Alberts SR, Heimbach JK. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 2012; 56: 972-981 [PMID: 22290335 DOI: 10.1002/hep.25629]
44. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143: 88-98. e3; quiz e14 [PMID: 22504095 DOI: 10.1053/j.gastro.2012.04.008]
45. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458; discussion 458-461 [PMID: 16135931 DOI: 10.1097/01.sla.0000179678.13285.fa]
46. Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH, Kim KH, Ahn CS, Kim MH, Lee SK, Sung KB, Ko GY. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 2010; 17: 476-489 [PMID: 19851704 DOI: 10.1007/s00534-009-0204-5]
47. Aoba T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, Nagino M. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg 2013; 257: 718-725 [PMID: 23407295 DOI: 10.1097/SLA.0b013e3182822277]
48. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176 [PMID: 22262022 DOI: 10.1159/000335597]
49. Le Treut YP, Grégoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, Castaing D, Soubrane O, Boillot O, Mantion G, Homayounfar K, Bustamante M, Azoulay D, Wolf P, Krawczyk M, Pascher A, Suc B, Chiche L, de Urbina JO, Mejzlik V, Pascual M, Lodge JP, Gruttadauria S, Paye F, Pruvot FR, Thorban S, Foss A, Adam R. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg 2013; 257: 807-815 [PMID: 23532105 DOI: 10.1097/ SLA.0b013e31828ee17c]
50. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol 2007; 47: 460-466 [PMID: 17697723 DOI: 10.1016/j.jhep.2007.07.004]
51. Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, Cherqui D, Castaing D, Ruszniewski P, Wolf P, Paye F, Salame E, Muscari F, Pruvot FR, Baulieux J. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant 2008; 8: 1205-1213 [PMID: 18444921 DOI: 10.1111/j.1600-6143.2008.02233.x]
52. Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, Hundley JC. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg 2011; 146: 953-958 [PMID: 21844436 DOI: 10.1001/archsurg.2011.186]
53. Nguyen NT, Harring TR, Goss JA, O'Mahony CA. Neuroendocrine Liver Metastases and Orthotopic Liver Transplantation: The US Experience. Int J Hepatol 2011; 2011: 742890 [PMID: 22254141 DOI: 10.4061/2011/742890]
54. Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, Boberg KM, Mathisen O, Gladhaug IP, Egge TS, Solberg S, Hausken J, Dueland S. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 2013; 257: 800-806 [PMID: 23360920 DOI: 10.1097/ SLA.0b013e3182823957]
55. Primrose JN. Surgery for colorectal liver metastases. Br J Cancer 2010; 102: 1313-1318 [PMID: 20424612 DOI: 10.1038/ sj.bjc.6605659]
56. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012; 59: 776-779 [PMID: 22692949 DOI: 10.1002/pbc.24215]
57. Cruz RJ, Ranganathan S, Mazariegos G, Soltys K, Nayyar N, Sun Q, Bond G, Shaw PH, Haberman K, Krishnamurti L, Marsh JW, Humar A, Sindhi R. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: new trends and future opportunities. Surgery 2013; 153: 150-159 [PMID: 23331862 DOI: 10.1016/ j.surg.2012.11.006]
58. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006; 107: 2108-2121 [PMID: 17019735 DOI: 10.1002/cncr.22225]
59. Ercolani G, Grazi GL, Pinna AD. Liver transplantation for benign hepatic tumors: a systematic review. Dig Surg 2010; 27: 68-75 [PMID: 20357454 DOI: 10.1159/000268628]
60. Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature. Liver Transpl 2010; 16: 930-942 [PMID: 20677284 DOI: 10.1002/lt.22106]
61. Orlando G, Adam R, Mirza D, Soderdahl G, Porte RJ, Paul A, Burroughs AK, Seiler CA, Colledan M, Graziadei I, Garcia Valdecasas JC, Pruvot FR, Karam V, Lerut J. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation--the European Liver Transplant Registry experience. Transplantation 2013; 95: 872-877 [PMID: 23354302 DOI: 10.1097/TP.0b013e318281b902]